Prolintane

Prolintane produces hERG potassium channel inhibition and QT interval prolongation in rodent cardiac models. Individuals with congenital or acquired long QT syndrome face compounded ventricular arrhythmia risk. No human cardiac safety data exist.

Prolintane's documented hERG channel inhibition in rodent models creates additive risk of ventricular arrhythmia when combined with other QT-prolonging drugs. Concurrent use is contraindicated.

Controlled human data show minimal cardiovascular effects at 10-20 mg oral doses. However, rodent models demonstrate hERG channel inhibition and QT prolongation at higher concentrations, indicating a dose-dependent cardiovascular risk profile. Individuals with pre-existing cardiovascular conditions face elevated risk, particularly at supratherapeutic doses.

As a norepinephrine reuptake inhibitor, prolintane may elevate blood pressure via increased adrenergic tone. This is a standard class-level contraindication for NDRI stimulants. Controlled human data at 10-20 mg showed minimal cardiovascular changes, but higher doses are expected to carry greater risk.

Class-level evidence indicates that stimulants may lower seizure threshold. No published data specifically address prolintane's effect on seizure susceptibility. Individuals with epilepsy or a history of seizures should exercise caution.

As a DAT-inhibiting stimulant, prolintane may precipitate or exacerbate psychotic symptoms via dopaminergic excess in the mesolimbic pathway. Hallucinations are documented in overdose settings and with chronic therapeutic-dose diphenhydramine co-administration. Individuals with a history of psychotic disorders face elevated risk.

Hyperthyroidism produces a state of sympathetic hyperactivity that may be exacerbated by catecholaminergic stimulants. This is a standard class-level contraindication for NDRI stimulants, inferred from the cocaine/methylphenidate class.

Prolintane was present in a case of intrauterine fetal death with spontaneous delivery, though concurrent use of cannabinoids, cocaine, nicotine, and hydrocodone prevents causal attribution. No teratogenicity, developmental toxicity, or reproductive safety studies have been published. The compound should not be assumed benign in pregnancy.

SSRIs, SNRIs, MAOIs, Tramadol

Prolintane functions as a serotonin transporter substrate at human (but not rat) transporters, inducing serotonin efflux. Co-administration with serotonergic agents — including SSRIs, SNRIs, MAOIs, and tramadol — creates risk of serotonin syndrome via compounded serotonergic excess. The tramadol interaction is rated lethal in the database. Severity ranges from relative (SSRIs) to absolute (MAOIs, tramadol).